Lek, a Sandoz company, receives certificate for successful sustainability reporting

  • For the first time, the Deloitte Company in Slovenia held a contest for the Green Frog Award at the end of last year and awarded the Green Frog Award for the best sustainability report.
  • Lek, a Sandoz company, has been producing its Sustainability Report for five years continuously with social responsibility indicators in its broadest sense.
  • The Sustainability Report 2014 published last year showed that Lek, a Sandoz company, improved all relevant indicators – economic, social and environmental.
4. 2. 2016

The Deloitte Company awarded the pharmaceutical company Lek, a Sandoz company, a certificate for creating a successful sustainability report for the first time in Slovenia. At the end of last year, the Deloitte Central European Sustainability Report Contest for the Green Frog Award was held in Slovenia. Today, the first-ever Green Frog Award was given for best Sustainability Report since its launch in 2001.

Lek, a Sandoz company, has been producing its Sustainability Report for five years now, outlining social responsibility indicators in its widest sense such as: environmental policy and measuring environmental impact, human resources policy, employment, occupational health and safety, quality of products, relations with business partners, and cooperation with local suppliers. The Sustainability Report 2014 published last year showed that Lek, a Sandoz company, improved all relevant indicators – economic, social and environmental.

The Green Frog Award ceremony was part of the event »Are you socially responsible?« presenting the results of the Deloitt’s research on corporate social responsibility. Last year, the research was carried out in Slovenia for the first time. Altogether 179 company social responsibility leaders from 10 Central European countries (Bulgaria, Czech Republic, Hungary, Lithuania, Latvia, Rumania, Serbia, Kosovo, Slovakia, and Slovenia) took part. According to respondents, the most important advantages of company’s social responsibility and sustainability are increased involvement of employees (65%), improved company image (55%), and better cooperation with local communities (53%).

Committee members Tanja Bolte, Director General of the Environment Directorate, Ministry of the Environment and Spatial Planning, Lucija Glavič, Ekvilib Institute, Urban Krajcar, Director General of the Directorate for Science, Ministry of Education, Science and Sport, Mojca Podržaj, The Manager’s Association of Slovenia, and Inga Turk, Environmental Agency of Slovenia, Head of Nature Conservation, evaluated the submitted companies’ annual sustainability reports in accordance with Deloitt’s methodology as well as social responsibility and sustainability guidelines. The Green Frog Award 2015 for the best Sustainability Report 2013/2014 was presented to the company Petrol d.d.; however, Lek, a Sandoz company, was ranked second along the company Telekom d.d.

* * *

Lek, a Sandoz company, is one of key pillars of the second-largest generic pharmaceutical company globally. Its role within Sandoz is to act as: a leading global development center for technologically demanding products and technologies; a global manufacturing center for active pharmaceutical ingredients and medicines; a competence center for the development of vertically integrated products; a Sandoz competence center in the field of development and manufacturing of biosimilar products; and, a supply center for the markets of Central and Eastern Europe (CEE), South East Europe (SEE) and Commonwealth of Independent States (CIS), and it is responsible for sales on the Slovenian market. For further information please visit http://www.lek.si/en.

Sandoz, a division of Novartis, is a global leader in generic pharmaceuticals, driving sustainable access to high-quality healthcare. Sandoz employs more than 26,000 people worldwide and supplies a broad range of affordable products to patients and customers around the globe.
The Sandoz global portfolio comprises approximately 1,100 molecules, which accounted for 2014 sales of USD 9.6 billion. Sandoz holds the global #1 position in biosimilars as well as in generic anti-infectives, ophthalmics and transplantation medicines. Sandoz also holds leading global positions in key therapeutic areas ranging from generic injectables, dermatology and respiratory to cardiovascular, metabolism, central nervous system, pain and gastrointestinal.
Sandoz develops, produces and markets finished dosage form (FDF) medicines as well as intermediary products including active pharmaceutical ingredients (APIs) and biotechnological substances. Nearly half of the Sandoz portfolio is in differentiated products – medicines that are scientifically more difficult to develop and manufacture than standard generics.
In addition to strong organic growth since consolidating its generics businesses under the Sandoz brand name in 2003, Sandoz has consistently driven growth in selected geographies and differentiated product areas through a series of targeted acquisitions, including Hexal (Germany), EBEWE Pharma (Austria), and Fougera Pharmaceuticals (US).
Sandoz is on Twitter. Sign up to follow @Sandoz_global at http://twitter.com/Sandoz_Global.

Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care and cost-saving generic pharmaceuticals. Novartis is the only global company with leading positions in these areas. In 2015, the Group achieved net sales of USD 49.4 billion, while R&D throughout the Group amounted to approximately USD 8.9 billion (USD 8.7 billion excluding impairment and amortization charges). Novartis Group companies employ approximately 119,000 full-time-equivalent associates. Novartis products are available in more than 180 countries around the world. For more information, please visit www.novartis.com.

* * *

This press release contains statements and conclusions based on projections of Lek’s future business operations. These estimates are derived from the best information currently available. In case these forecasts prove unreliable, the actual results could prove different from those projected.

- end -

For additional information contact:
Katarina Klemenc
Corporate Communications
Lek Pharmaceuticals d. d.
Phone: +386 1 580 22 43
Fax: +386 1 580 24 32